化合物P7C3-OME | 313268-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 化合物P7C3-OME
• 英文名称: 1-(3,6-dibromo-9H-carbazol-9-yl)-3-((3-methoxyphenyl)amino)propan-2-ol
• 英文别名: P7C3-OMe；1-(3,6-dibromocarbazol-9-yl)-3-(3-methoxyanilino)propan-2-ol
• CAS: 313268-18-7
• 化学式: C₂₂H₂₀Br₂N₂O₂
• 分子量: 504.221
• InChiKey: LEICNUMXFWNCSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  680.4±55.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥100mg/mL（198.33毫摩尔）

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 储存条件：
  -20°C，密闭保存，干燥条件下使用

制备方法与用途

P7C3-OMe 是一种促进神经元生长的化合物，在治疗神经精神疾病或神经退行性疾病时表现出良好的效果。R-对映体的活性明显高于S-对映体。

反应信息

• 作为反应物：
  描述：

  化合物P7C3-OME 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以5.7 mg的产率得到3,6-二溴-beta-氟-N-(3-甲氧基苯基)-9H-咔唑-9-丙胺
  参考文献：
  名称：

  Pro-neurogenic compounds

  摘要：

  这项发明通常涉及刺激神经发生（例如，后生神经发生，例如，后生海马神经发生）并保护免受神经细胞死亡的影响。

  公开号：

  US09095571B2
• 作为产物：
  描述：

  1-chloro-3-((3-methoxyphenyl)amino)propan-2-ol 在 sodium hydride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 化合物P7C3-OME
  参考文献：
  名称：

  Aminopropyl carbazole analogues as potent enhancers of neurogenesis

  摘要：

  Neural stem cells are multipotent and self-renewing cells that can differentiate into new neurons and hold great promise for treating various neurological disorders including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Small molecules that can trigger neurogenesis and neuroprotection are particularly useful not only because of their therapeutic implications but also because they can provide an invaluable tool to study the mechanisms of neurogenesis. In this report, we have developed and screened 25 aminopropyl carbazole derivatives that can enhance neurogenesis of cultured neural stem cells. Among these analogues, compound 9 demonstrated an excellent proneurogenic and neuroprotective activity with no apparent toxicity. We believe that compound 9 can serve as an excellent lead to develop various analogues and to study the underlying mechanisms of neurogenesis. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.066

文献信息

• 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用
  申请人：上海欧坤生物医药科技有限公司

  公开号：CN113402444A

  公开（公告）日：2021-09-17

  本发明涉及一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用，所述咔唑类化合物的结构通式如式(I)所示，其中R1选自卤素、羟基或C1‑C6烷氧基；R2和R3中的每一个独立选自(a)氢或甲酰基；(b)C5‑C8杂环基或芳基，其任选地被0‑4个R4取代；其中R4选自C1‑C6烷氧基、C2‑C6烯氧基、C2‑C6炔氧基或卤素；X1和X2中的每一个独立选自氢或卤素；Z1和Z2中的每一个独立选自氢、氰基或‑SOp‑R5；其中p选自0、1或2；R5选自C1‑C6烷基、C2‑C6烯基、C2‑C6炔基；n和m中的每一个独立选自1、2、3或4。本发明的化合物对糖脂代谢类疾病的治疗作用显著提升。
• PRO-NEUROGENIC COMPOUNDS
  申请人：McKnight Steven L.

  公开号：US20120022096A1

  公开（公告）日：2012-01-26

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生），和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性体重减轻，以及与正常衰老、化疗等相关的认知衰退方面具有治疗益处。
• Pro-Neurogenic Compounds
  申请人：McKnight Steven L.

  公开号：US20130040977A1

  公开（公告）日：2013-02-14

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生）和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病的治疗方面具有治疗益处，例如精神分裂症、重度抑郁症、躁狂症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性减重，以及与正常衰老、化疗等相关的认知衰退。
• Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds
  申请人：UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS OF THE

  公开号：US20130184271A1

  公开（公告）日：2013-07-18

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  本技术通常涉及化合物和方法，用于刺激神经发生新生（例如，出生后神经发生新生，包括出生后海马和下丘脑神经发生新生）和/或保护神经细胞免受细胞死亡。本文介绍了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、外周神经损伤、与各种疾病相关的生理性体重下降以及与正常衰老、化疗等相关的认知衰退中具有治疗益处。
• Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds
  申请人：Board of Regents of the University of Texas System

  公开号：US20130184300A1

  公开（公告）日：2013-07-18

  This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.

  本发明通常涉及刺激神经发生（例如，产后神经发生，例如，产后海马神经发生）和保护神经细胞免受死亡的影响。